SK Biopharmaceuticals Forecast, price target & analysts
SK Biopharmaceuticals Target price 2025 - Analyst rating & recommendation
SK Biopharmaceuticals Classifications & Recommendation:
SK Biopharmaceuticals Price Target
| Target Price | KRW144,267.00 |
| Price | KRW114,000.00 |
| Potential |
26.55%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target SK Biopharmaceuticals 2026 .
The average SK Biopharmaceuticals target price is KRW144,267.00.
This is
26.55%
register free of charge
KRW170,000.00
49.12%
register free of charge
KRW61,000.00
46.49%
register free of charge
|
|
| A rating was issued by 16 analysts: 11 Analysts recommend SK Biopharmaceuticals to buy, 4 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the SK Biopharmaceuticals stock has an average upside potential 2026 of
26.55%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Billion KRW | 354.89 | 534.04 |
| 44.16% | 50.48% | |
| EBITDA Margin | -6.42% | 18.63% |
| 86.62% | 390.28% | |
| Net Margin | -9.27% | 11.52% |
| 83.64% | 224.34% |
15 Analysts have issued a sales forecast SK Biopharmaceuticals 2024 . The average SK Biopharmaceuticals sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an SK Biopharmaceuticals EBITDA forecast 2024. The average SK Biopharmaceuticals EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 SK Biopharmaceuticals Analysts have issued a net profit forecast 2024. The average SK Biopharmaceuticals net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2027
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share KRW | -419.89 | 785.50 |
| 76.42% | 287.07% | |
| P/E | 161.68 | |
| EV/Sales | 18.51 |
2 Analysts have issued a SK Biopharmaceuticals forecast for earnings per share. The average SK Biopharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the SK Biopharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
SK Biopharmaceuticals...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
